At their semiannual meeting November 19th, 2021, the Assembly of Members of the Biobanking and BioMolecular resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC) elected new members of the Steering Committee. Outgoing Assembly of Members Chair Hemma Bauer (AT) and Vice-Chair Olli Carpen (FI) will be replaced by Philippe Desmeth (BE) and Priit Tamm (EE), respectively. In the Finance Committee, previous Chair Luisa Minghetti (IT) will serve as Vice-Chair, and previous Vice-Chair Mark Debono (MT) will now serve as Chair.
“I would like to send a heartfelt thanks to the outgoing Chair and Vice-Chair for their longstanding support and guidance, steering the BBMRI community through an exciting period of BBMRI-ERIC’s growth and development of its core services with their steadfast engagement,” says BBMRI-ERIC Director General Prof. Jens K. Habermann. “At the same time I give a very warm welcome to the new Chairs and Vice-Chairs and look forward to implementing our new Work Programme under their guidance.”
The Steering Committee is responsible for supporting and guiding the Director General of BBMRI-ERIC and Headquarter team between the sessions of the Assembly of Members in implementing decisions, including the Strategic Plan, the Work Programme and the budget.
Members of the Steering Committee serve 1-year terms.
BBMRI-ERIC is one of the largest ERICs in the biomedical field with currently 23 members: 17 member states and 6 observers, including IARC (WHO). With its headquarters in Graz, Austria, BBMRI-ERIC’s mission is to facilitate access to sample and data as well as to biomedical resources. This is facilitated through services and advancements in the areas of Ethical, Legal and Societal Issues (ELSI); Quality Management (QM); Information Technology (IT); Biobank Developments (BBD); Public Affairs (PA); and Outreach, Education & Communications (OEC).
BBMRI-ERIC is currently active in 22 different EU projects and brings together all main players from the biobanking and life science field – researchers, biobankers, industry, and patients – in order to advance and implement precision medicine.